<name>TheraPPI</name> <description>TheraPPI develops therapeutics that target disease-relevant protein‑protein interactions (PPIs) within the RAS‑MAPK signaling pathway. Its lead oncology program employs a novel mode of action that directly kills cancer cells, avoids resistance mechanisms, and stimulates anti‑tumor immunity. By focusing on PPIs, the company aims to deliver treatments for cancers and rare diseases that are not addressable by conventional
Funding
Funding not disclosed
Founders
Product
Problem
Advanced cancers often exhibit poor prognoses due to resistance to current RAS-MAPK inhibitors. The RAS-MAPK signaling pathway is hyperactivated in over 40% of human cancers, and mutations in this pathway also cause rare diseases. Existing inhibitors are limited by cancer resistance and their inability to cure these rare diseases.
Solution
TheraPPI is developing small molecules that modify protein interactions within the RAS-MAPK pathway to overcome cancer drug resistance and treat rare diseases. Their lead program targets a novel protein interaction in the RAS-MAPK pathway, employing a unique mechanism of action. This approach directly kills cancer cells, prevents the induction of resistance, and activates an anti-tumoral immune response. The goal is to improve clinical outcomes for patients with advanced cancers by circumventing resistance and enhancing the effectiveness of immunotherapies.
Target Audience
The primary target audience includes patients with advanced cancers where the RAS-MAPK signaling pathway is hyperactivated, as well as individuals suffering from rare diseases caused by RAS-MAPK-activating mutations.
Features
- Small molecule therapeutics designed to modulate protein-protein interactions (PPIs) within the RAS-MAPK pathway.
- Novel mechanism of action that directly induces cancer cell death.
- Prevents the development of cancer resistance to treatment.
- Activates an anti-tumoral immune response to enhance therapeutic efficacy.
- Targets a novel protein interaction within the RAS-MAPK pathway.